Image

Direct Transcranial Electrical Stimulation in Tobacco Addiction (tDCS)

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

In summary, there are currently many therapeutic tools for achieving some degree of control or even cessation of tobacco addictive use. No single therapy seems to have proven itself sufficiently effective to be the preferred treatment axis in the management of this addiction. We can also point out that so far the main treatments aimed at reducing or controlling the craving phenomenon are of a pharmacological nature, thus exposing the participants to the side effects inherent to this type of treatment. In this perspective, the establishment of non invasive brain stimulation (TdCS), acting in a targeted manner on craving and whose effects would be mild and transient, appears quite justified, especially in addition to psychotherapy. In the context of the management of addictive pathologies, the choice of smoking dependence seems relevant to us insofar as this addiction represents a major public health problem.

Eligibility

Inclusion Criteria:

  • Men and women over the age of 18
  • Nicotine dependent subjects according to the Fagerström test (score ≥5)
  • Subjects consuming daily tobacco.
  • Subjects understanding and reading French and able to express themselves in this language.
  • Signed informed consent to participate indicating that the subject has understood the purpose and the procedures required by the study and agrees to participate in the study and to comply with the requirements and limitations of this study
  • Affiliation to the French social security scheme or beneficiary of such a scheme.
  • No other method to decrease or stop smoking at the same time as the study.

Exclusion Criteria:

  • Guardianship
  • Pregnant or lactating woman
  • Patient under AME
  • Subject being in the exclusion period of another study or provided for by the "National Volunteer File".
  • Subjects with intracranial hypertension
  • Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator.
  • Treatment with buproprion or varenicline in progress
  • Episode or family history of epilepsy, convulsion.
  • Disease causing damage to the brain (aneurysm, tumor, ...).
  • Cochlear or ocular implant.
  • Stimulator or cardiac defibrillator.
  • Presence of metal in the skull (clip on aneurysm, prosthesis, ...).
  • Eczema on the scalp.

Study details

Adults (Male and Female Subjects) With Tobacco Dependence

NCT04209153

Assistance Publique - Hôpitaux de Paris

27 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.